Skip to main content
Caplight Logo









Lunac Therapeutics

Lunac Therapeutics

Private
LeedsHealthcare & Life Scienceshttps://www.lunactherapeutics.com/

Last Round

VC Round

May 13, 2021

Total Funding Raised

$7.45M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Lunac Therapeutics is a drug discovery company developing next-generation oral anticoagulants to treat and prevent thrombotic events without the bleeding risk associated with current therapies.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

Factor XIIa inhibitorFXIIa inhibitoranticoagulant therapyblood thinnerthrombosissmall molecule drugsafer anticoagulantsdrug discoverypreclinical developmentfirst-in-class drugbiotechblood clot preventionanticoagulant without bleeding riskpharmaceutical licensinghemostasisuniversity spin-out

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Lunac Therapeutics Comparables

Compare Lunac Therapeutics with similar companies based on industry and business-model similarity.

Lunac Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Aronora, Inc.
84%
Anthos Therapeutics
77%
Bayer AG
74%

Lunac Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMay 13, 2021
GrantDec 12, 2019
Series ANov 14, 2019

Lunac Therapeutics Investors

Notable investors and investment history

Lunac Therapeutics investors
InvestorRounds
University of LeedsSeries A
Epidarex CapitalVC Round, Series A
Innovate UKGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 24, 2026

    Monthly visitors increased 36% MoM.

  • Jun 18, 2026

    Monthly visitors increased 81% MoM.

Lunac Therapeutics Filings

Explore SEC and related filing metadata, where available.

Lunac Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Lunac Therapeutics's valuation, stock price, and market status.

Is Lunac Therapeutics a public or private company?

Lunac Therapeutics is a private company.

What is the current stock price of Lunac Therapeutics?

Lunac Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Lunac Therapeutics worth (valuation)?

Valuation information for Lunac Therapeutics is not publicly available.

Can I buy Lunac Therapeutics stock?

Lunac Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Lunac Therapeutics's last funding round?

Funding round information for Lunac Therapeutics is not publicly available.

Who are the main investors in Lunac Therapeutics?

Investor information for Lunac Therapeutics is not publicly disclosed.

Will Lunac Therapeutics IPO soon?

No public IPO plans have been announced for Lunac Therapeutics.

How can I track Lunac Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Lunac Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLeeds
Employee Range1
Year Founded2018
Last FundingMay 13, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?